Latest news with #CORAL
Associated Press
03-07-2025
- Business
- Associated Press
Celebrate Ocean Conservation with SEKKISEI's SAVE THE BLUE 2025 Limited Edition Launch Supporting Coral Reefs Around the World, One Bottle at a Time
NEW YORK, July 3, 2025 /PRNewswire/ -- Since 2009, SEKKISEI has championed ocean conservation through its global SAVE THE BLUE initiative. In 2025, the brand continues this mission with the launch of a Limited Edition SAVE THE BLUE Lotion, designed to raise awareness and funds for the protection of marine ecosystems and the preservation of coral reefs. For the seventh consecutive year, SEKKISEI is proudly partnering with the Coral Reef Alliance (CORAL)–a global nonprofit organization dedicated to safeguarding coral reefs and the ocean life that depends on them. CORAL's science-based, holistic approach addresses water quality issues, unsustainable fisheries, and the impacts of climate change to help coral reefs not just survive–but thrive. In honor of this year's campaign, from July 1 - July 31, SEKKISEI will donate $1 for every Limited Edition SAVE THE BLUE Lotion ($88, 16.9 fl oz / 500 mL) sold through its U.S. e-commerce site, supporting CORAL's work across the United States and the Caribbean. This ultra-hydrating liquid lotion is a cult-favorite J-Beauty essential. Lightweight and nutrient-rich, it preps skin to better absorb treatments and enhances radiance with every use. Perfect for morning and night, this lotion can be used as a traditional liquid moisturizer or a hydrating mask for an instant refresh. Since launching SAVE THE BLUE, SEKKISEI has planted more than 20,000 coral polyps globally and expanded its conservation efforts to eight countries. The initiative has restored over 122 million cm² of reef habitat, helping build a more resilient ocean for future generations. For more information on SAVE THE BLUE and the products, go to About SEKKISEI: SEKKISEI, a Japanese skincare brand trusted since 1985, has been setting new standards in hydration, clarity, and even skin tone. SEKKISEI blends ancient Asian herbal remedies with cutting-edge Japanese scientific research to deliver highly effective skincare solutions that are accessible to all, without gender boundaries or age limits. Infused with carefully selected botanicals from hundreds of herbs, their formulas deeply hydrate, brighten, and refine skin tone, unlocking radiant, healthy skin. Media Contact: PURPLE PR Email: [email protected] Learn more at View original content to download multimedia: SOURCE Kose America
Yahoo
13-06-2025
- Health
- Yahoo
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Health
- Yahoo
Avextra Cannabis extract can potentially reduce symptom burden for late palliative patients
Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL study. New Study Demonstrates Significant Symptom Relief for Late-Stage Palliative Patients Treated with Cannabis-based Medicines Bensheim, Germany – 13th June 2025 – According to the World Health Organization, an estimated 56.8 million palliative care patients worldwide suffer from significant symptom burden every year. In palliative care — particularly for oncology patients — effective symptom management is essential to maintaining dignity, comfort, and quality of life in the final stages of illness. Despite advances in conventional therapies, many patients continue to suffer from uncontrolled pain, anxiety, and other distressing symptoms. The CORAL study offers promising evidence that cannabinoid-based medicines may play a critical role in addressing this unmet need. The CORAL study (CannabinOid-TheRapie in der PALliativmedizin or Cannabinoid Therapy in Palliative Care) is a non-interventional, parallel group study designed to examine the reduction of symptom burden in patients receiving end-of-life care. Led by Prof. Dr. med. Sven Gottschling from Universitätsklinikum des Saarlandes in Homburg, 150 patients in advanced palliative stages were enrolled in the study, with over 80% being oncology patients. 100 of them were additionally treated with the cannabis extract Avextra 10:10 (THC/CBD), the other 50 with a non-cannabinoid treatment. Key Findings from the CORAL Study Significant Symptom Reduction: Patients treated with Avextra's extract showed statistically and clinically significant improvement in MIDOS scores (a palliative symptom assessment tool), while the control group's symptoms worsened. 68% of patients treated with Avextra showed clinically relevant improvement (≥20%). Mental Health Improvements: Stress, anxiety, and depression levels (measured by DASS-21) improved in the Avextra group, but worsened in the control group. All were statistically and clinically superior to the control group ; 50% were stress responders, and over 20% improved in all three DASS categories. Quality of Life Gains: Patients reported better outcomes across multiple domains in the EORTC QLQ-C15-PAL questionnaire, a quality-of-life tool validated for palliative care. Nearly 25% of patients in the Avextra group showed clinically relevant quality of life improvement. Lower Co-medication Burden: Avextra-treated patients require significantly less use of sedatives, sleep aids, benzodiazepines, and muscle relaxants. High Tolerability: The extract was well tolerated, with fewer than 15% of patients reporting any adverse reactions and only three dropouts due to side effects. Principal investigator Prof. Dr. Sven Gottschling, Head Physician of the Center for All-Age Palliative Medicine and Paediatric Pain Therapy at the UKS in Homburg, presents the study results during the 6th Medicinal Cannabis Congress in Berlin. He stated: "The CORAL study is another significant contribution to improving the treatment of those with serious, terminal diseases. We would like to thank our study partner Avextra: Together, we are committed to improving symptom burden reduction of those affected and further optimizing palliative care treatment options for patients and caregivers." Enhanced quality of life towards the end of lifeThere is a significant need for interdisciplinary studies, particularly in palliative care. This was highlighted in February by representatives of the Leopoldina (German National Academy of Sciences) and other scientific experts in Berlin. "Avextra's goal is to further improve symptom relief for palliative care patients. We are happy that our products appear to be helping to achieve that, and this motivates us to develop even better, innovative dosage forms for this patient group," said Dr. Bernhard Babel, CEO of Avextra. About Avextra AG Avextra is one of Europe's leading vertically integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based in Germany, the company works in close collaboration with doctors, pharmacists and researchers to develop and produce innovative Cannabis-based Medicines. Avextra controls the entire value chain – from cultivation to EU-GMP certified extraction and manufacturing in Germany. Avextra´s products are distributed in federally regulated cannabis access programmes across Europe. Going forward, Avextra will keep conducting studies focusing on the clinical outcomes of cannabis-based medicines on patients' overall reduction of symptom burden. Clinical trials represent a key element of the German biotech company's strategic focus towards getting a registered medicine. Learn more at and stay up to date at LinkedIn: Avextra Media Enquiries: For media enquiries or to set up an interview please contact: Email: press@ Phone: +49 30 408174037 Attachment Prof. Dr. med. Sven Gottschling, Principal Investigator for the CORAL in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by the study's UK Lead Investigator, Professor Philip Molyneaux NEW HAVEN, Conn., June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2% (p<0.0001), 53.4% (p<0.0001), and 47.9% (p<0.01), respectively, compared to a placebo reduction from Baseline of 16.9%1. Statistically significant improvements were observed across secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups. "The CORAL trial is the first positive Phase 2b parallel group study for the treatment of chronic cough in patients with IPF, a significant milestone for patients and Trevi," said Jennifer Good, President and CEO of Trevi Therapeutics. "Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved therapies for chronic cough in this population and with these data, Trevi is one step closer to addressing this unmet need." "In my patients with IPF, chronic cough is one of the most challenging comorbidities I face clinically," said Philip Molyneaux, MD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, London. "IPF treatments focus on slowing disease progression but have not shown benefit on chronic cough, which can lead to poor health outcomes and quality of life. I am excited about the CORAL data and the potential continued development of nalbuphine ER for this significant unmet need among IPF patients." Primary Endpoint – Relative Change from Baseline in 24-hour Cough Frequency (coughs per hour) at Week 6Placebo1 (N=39) Haduvio 27 mg BID (N=42) Haduvio 54 mg BID (N=43) Haduvio 108 mg BID (N=40) Baseline 24-hour Cough Frequency (coughs/hour) 29.4 24.6 28.0 31.5 Relative Change from Baseline in 24-hour Cough Frequency at Week 6 -16.9 % -47.9% (p<0.01) -53.4% (p<0.0001) -60.2% (p<0.0001) Placebo-adjusted difference - -30.9 % -36.5 % -43.3 %1One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat (mITT) population. Inclusion of the patient in the placebo group would have resulted in an increased cough frequency from Baseline in the placebo group and much greater placebo-adjusted differences. The primary efficacy endpoint was the relative change in objective 24-hour cough frequency (coughs per hour) for the mITT population at the end of Week 6 versus Baseline for Haduvio compared to placebo. The mITT population consists of all randomized patients who received at least one dose of study drug or placebo. Additional Trial Results A rapid reduction was seen in 24-hour cough frequency at Week 2 with Haduvio, the first time point measured. A 50% reduction in 24-hour cough frequency at Week 6 vs Baseline was seen in 65% of patients on 108 mg BID Haduvio (p<0.001), 63% of patients on 54 mg BID Haduvio (p<0.001) and 60% of patients on 27 mg BID Haduvio (p<0.001) dose groups, compared to 19% of placebo patients. A statistically-significant response was observed on the cough-severity numerical rating scale (CS-NRS), a secondary endpoint, at Week 6 on Haduvio in both the 108 mg BID and 54 mg BID dose groups. There was a mean reduction on a 0 – 10 scale of 3.0 points on the 108 mg BID (p<0.05), 3.2 points on the 54 mg BID (p<0.01) and 2.0 points on the 27 mg BID (p=0.46) dose groups compared to a 1.5-point reduction on placebo at Week 6. The 108 mg BID and 54 mg BID dose groups were statistically-significant (p<0.01) on the patient-reported outcome E-RS®: IPF Cough Subscale, a secondary endpoint, with mean relative change from Baseline of -42.4% and -43.1%, respectively at Week 6, compared to -23% for those on placebo at Week 6. The 27 mg BID dose group was not statistically-significant with a mean relative change from Baseline of –31.6%. Discontinuation rates due to adverse events were similar in the combined Haduvio groups (5.6%) and placebo group (5.0%). The safety profile observed in the trial was generally consistent with the known safety profile of Haduvio from previous trials. The most common adverse events experienced included: nausea, vomiting, constipation, dizziness, headache, fatigue, somnolence, and dry mouth. Serious adverse events (all non-fatal) were reported for four patients (10.0%) in the placebo group and for two patients (1.6%) across all Haduvio doses combined. James Cassella, Ph.D., Chief Development Officer of Trevi Therapeutics added, "We are very pleased with the findings from the CORAL trial, which continue to demonstrate the robust cough suppressant activity of nalbuphine ER. The study has provided critical dose-ranging data to inform the planning of our Phase 3 program. We intend to request an End-of-Phase 2 meeting with the FDA to discuss our plans for initiating the Phase 3 program for the treatment of chronic cough in patients with IPF. I would like to take the opportunity to thank the patients, investigators and site staff for moving research forward for these patients. We look forward to advancing development of this program." Conference Call/Webcast The Company will host a conference call and webcast to review the topline results today, June 2nd, at 8:30 a.m. ET. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About the CORAL TrialThe Phase 2b Cough Reduction in IPF with Nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three Haduvio doses or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for Haduvio compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact Jonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media Contact Rosalia Scampoli914-815-1465rscampoli@ 2Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis as collected in the EXACT® (EXAcerbation of Chronic pulmonary disease Tool). EXACT© 2013, Evidera, Inc. All rights reserved. View original content to download multimedia: SOURCE Trevi Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Indian Express
25-04-2025
- Science
- New Indian Express
Ozone pollution puts essential crops in peril, reveals new study
The world's essential food grains wheat, rice and maize are facing a silent threat from escalating surface ozone pollution. A groundbreaking study by Professor Jayanarayanan Kuttippurath and his team at the Centre for Ocean, River, Atmosphere and Land Sciences (CORAL), IIT Kharagpur, has sounded the alarm on a growing but under-recognised threat to India's food security: surface ozone pollution. Published in the journal Environmental Research, the study titled 'Surface ozone pollution-driven risks for the yield of major food crops under future climate change scenarios in India' combines historical trends with future projections using data from the Coupled Model Intercomparison Project Phase-6 (CMIP6). According to the researchers, potential oxidant surface ozone is increasingly damaging crop productivity by infiltrating plant tissues and disrupting essential physiological functions, particularly photosynthesis. Under high-emission scenarios like SSP3-7.0 and SSP5-8.5, wheat yields could decline by up to 20, while rice and maize could see losses of around 7% each after 2050. The Indo-Gangetic Plain and Central India are identified as especially vulnerable, with ozone exposure during crop growth stages potentially exceeding safe limits by up to six times. The threat is compounded by what the study refers to as a 'climate penalty' during India's rabi and post-kharif seasons, which is expected to worsen surface ozone levels. Stating that the situation is deeply concerning, the study noted that findings have significant implications for our agricultural productivity and our progress toward the United Nations Sustainable Development Goals of zero hunger and no poverty. Despite the launch of the National Clean Air Programme (NCAP) to tackle urban air pollution, agricultural regions continue to be overlooked. The study stresses the urgent need for crop-specific air quality policies and the promotion of clean energy and low-emission farming techniques. The research also explores biological mechanisms of ozone damage, noting that about 45% of surface ozone is absorbed through plant stomata, generating harmful reactive oxygen species that degrade critical enzymes such as RuBisCO. This disruption in photosynthesis reduces crop yields significantly. While several previous studies in India have used short-term data to estimate yield loss from ozone exposure, this study stands out for its comprehensive assessment of future scenarios. It urges policymakers to transition from high-emission development pathways to more sustainable models such as SSP1-2.6, which could help limit crop damage and preserve national and global food security. As India remains a major exporter of food grains to Asia and Africa, any significant loss in agricultural output could have global repercussions. The researchers call for immediate and coordinated actions to integrate air quality management into agricultural policy frameworks.
